Confirmed Preliminary Control Closed Transaction verified Consumer Health

Biofreeze acquired by Reckitt Benckiser Group plc

Reckitt Benckiser Group plc acquired Biofreeze, a consumer healthcare brand, on Jul 11, 2021.

Preliminary: The announcement date, completion date, value basis, EV/revenue, EV/EBITDA, metric basis, value notes and transaction value are not yet independently verified. The EV/EBITDA is outside the usual range for comps, so treat it with caution.

Transaction summary

Target
Biofreeze
Announced
2021-02-01(unverified)
Completed
2021-07-11(unverified)
Geography
-
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-07-26
Latest update
2026-10-31

Value and multiples

100% enterprise value

USD 1.1B

Unverified

100% enterprise value | USD

Basis: Undisclosed

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

EV / revenue

4x

Unverified

Period not stated

Basis: FundComb estimate

EV / EBITDA

29x

Unverified

EBITDA basis not stated

Basis: FundComb estimate

Amounts paid and other reported values

Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.

Undisclosed: USD 1.1B

Public web evidence verifies the acquisition but does not disclose consideration.

Basis

  • Pasted spreadsheet values only; no underlying revenue, EBITDA, or enterprise value disclosed in supplied public evidence.

Other reviewed estimates

Earlier estimates and their sources.

Reckitt Benckiser Group plc (LSE:RB) completed the acquisition of TheraPearl and Biofreeze from Performance Health, LLC. - marketscreener.com
EV / revenue 4x | EV / EBITDA 29x
Open evidence

Source summary

Reckitt Benckiser Group plc (LSE:RB) completed the acquisition of TheraPearl and Biofreeze from Performance Health, LLC. - marketscreener.com

Confirmed
Open via Google News

Continue your research

Explore more comps →